A Silver nanoparticle based hydrogel prepared by green synthesis

Slides:



Advertisements
Similar presentations
Study Objectives and Questions for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Advertisements

Protocol Development.
HOT TOPICS ARCHIVING OR HOW NOT TO DUMP YOUR RUBBISH!
Finished Pharmaceutical Product Specifications
Reprocessing Biotech Products
Stability data required by WHO-PQP Mercy Acquaye.
Optimal Drug Development Programs and Efficient Licensing and Reimbursement Regimens Neil Hawkins Karl Claxton CENTRE FOR HEALTH ECONOMICS.
BY: PATEL MINAL NARAN U29/35243/2010 SUPERVISOR: DR. P. M. NJOGU
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
World Health Organization
Determine impurity level in relevant batches1
Title Page Name of PI and Co PI March 6, 2008 Oversight Committee Presentation.
1 Certification Chapter 14, Storey. 2 Topics  What is certification?  Various forms of certification  The process of system certification (the planning.
Nanotechnology in Drug Discovery- Development and Delivery
ES305: Virtual Tools in Engineering Design: The Eng. Design Process James Carroll, Associate Professor Electrical and Computer Engineering.
Stefan Franzén Introduction to clinical trials.
Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.
Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
Processing and Product Quality Issues Keith Wonnacott Ph.D. Office of Cellular, Tissue, and Gene Therapies E BC R Moving from Investigational to Licensed.
Finding a way or making one. Labor’s headquarter is in Rome Labor.
Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
Introduction to Analytical Chemistry
Stefan Franzén Introduction to clinical trials.
Utilizing Science & Technology and Innovation for Development Study the interaction of nanoparticles with proteins Marriott Hotel- Amman, August 13th,
By Professor Ranjit Roy Chaudhury WHO-SEA ACHR BANGKOK 12 October Quality of Research Supported by SEARO in countries of the Region.
Exploratory IND Studies
1 / 9 ASTM D19 Method Validation Procedures William Lipps Analytical & Measuring Instrument Division July, 2015.
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
Important informations
The Use of Scientific Advisory Boards An Invaluable Tool in Drug Development Dr Robert Miller Chief Medical Officer Fulcrum Pharma Developments 19 th Annual.
Molecule-to-Market-Place Quality
The New Drug Development Process (www. fda. gov/cder/handbook/develop
Product Management. Facts about Product Management Many managers realized that investment in INNOVATION is critical for future growth & even in the survival.
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
Scientific Investigation Unit 3. Aim and purpose The aim of this unit is to enable learners to explore the protocols associated with scientific investigations.
Stability Trials ASEAN Guidelines. The Objective of a stability study To determine the shelf life, namely the time period of storage at a specified condition.
Malaysia, EVALUTION OF DOSSIERS IN WHO- PREQUALIFICATION PROJECT MULTISOURCE TB-DRUGS Evaluation of bioavailability/bioequivalence data Based,
Pharmacists Perceptions of the Development of Herbal Medicines in Iran Asghari G. Faculty of Pharmacy and Pharmaceutical Sciences Isfahan University of.
Horizon 2020 – 2016 Transport Call
Substance Structure, production process and indented use Is there adequate published safety data and exposure data for this substance to meet current GRAS.
Progression of New Drug: From Idea to Public Consumption Chris DeFarlo Writing in the HLTH Professions Unit 2 Prof. Edwards.
Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.
การยับยั้งจุลินทรีย์โดยใช้วัสดุซิลเวอร์นาโน ที่ได้จากเคมีสีเขียวเพื่อประยุกต์ใช้ในการ บำบัดน้ำ ( Antibacterial Ability of Ag and Ag/AgCl Nanoparticles.
httpwww.youtube.com/watch?v=DhxD6sVQEYc:// The Drug Discovery Process.
In the name of God. Common Technical Document On Biotech.
Rob Connatser NSS Instrument Work Packages and XLPM.
Clinical Trials.
Responsibilities of Sponsor, Investigator and Monitor
REGULATORY REQUIREMENTS FOR PREFORMULATION STUDIES
FORMULATION AND EVALUATION OFALKANET ROOT LOADED
BIOSYNTHESIS OF SILVER NANOPARTICLES USING MELIA DUBIA LEAF AQUEOUS EXTRACT AND ITS ANTIBACTERIAL ACTIVITY   Submitted by:
Responsibilities of Sponsor, Investigator and Monitor
Synthesis of Copper Nanoparticles In Nonpolar as Lubricant Additives
- Pharmaceutical Equivalence Study
Final Project Dissemination Meeting
Drug Discovery &Development
LNH Pharma A Trusted Partner.
Clinical Trials — A Closer Look
From Bench to Clinical Applications: Money Talks
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease Torres et al. Am J.
EUROPEAN UNION EUROPEAN SOCIAL FUND OPERATIONAL PROGRAMME
Pediatric Therapeutics Still working to get it right for kids
Pharmaceuticals Industry
Regulatory Perspective of the Use of EHRs in RCTs
Quality guidelines on impurities
Quality guidelines on impurities
Presentation transcript:

A Silver nanoparticle based hydrogel prepared by green synthesis Wound Healing Gel A Silver nanoparticle based hydrogel prepared by green synthesis

Novelty/Inventive component The product uses nanoparticle of silver formed by green synthesis Social Relevance Its an OTC product with vast market potential Use of herbal product has better market acceptability Hence very much required by the society Commercial Potential The new product uses 0.02% silver nitrate while the traditional ones like Silverex® (Ranbaxy) uses 0.2% w/w. It’s a 10 times reduction in the quantity of silver used.

Proof of concept: Wound healing activity in Swiss Albino Wistar Rats.

PROPOSAL AIMS AT Aim: Seeking approval for further investigation regarding safety & stability of the product & conduct clinical trial Key deliverables: Evaluation of safety & stability of the product using analytical/bio-analytical method following ICH guidelines Evaluation of microbial load in final product & identification of suitable preservative. Conducting Phase – I clinical trial.

To establish safety, stability and efficacy through clinical trials OBJECTIVES To establish safety, stability and efficacy through clinical trials Work Plan Step 1 – Assessment of safety of the product: Skin irritation studies will be carried out using rabbits by Drazie test. The irritancy score shall be computed and based on response of skin. Step 2 - Stability of the product: Effect of varying storage conditions on product stability/efficacy will be evaluated using suitable analytical/ bio-analytical method as per ICH guideline. Step 3 – Evaluation and reduction of microbial load: Microbial load of the formulation will be assessed and attempt will be made to reduce the microbial load by incorporating preservative at optimum concentration. Step 4 – Clinical trials: The safety/efficacy of the product will be proven through clinical trials.

ENVISAGED OUTCOME OF THE STUDY The outcome of the project would be a comparatively cost effective formulation for treatment of wound healing that will be based on newer nanotechnology. The product will demonstrate adequate stability & safety. After successful safety & stability test and DCGI approval, this project will go to Phase-2 for clinical trail study.

PRELIMINARY WORK UNDERTAKEN

Microbial efficacy by Agar Well diffusion Assay Concentration (µg/ml) Average zone of inhibition (mm) E.coli S.aureus 10 16 15 20 17 40 18 80 19

Characterization of nanoparticles: UV Spectroscopy

Crystallinity Studies: XRD

Electron microscopy (SEM)

Infrared Spectroscopy

Wound healing Activity : ays 7 & 14

Wound healing Activity: Days 14 & 21

Preparation of formulation Silver Nitrate Addition of herbal extract Formation of colloidal nanoparticles after heating Addition of gelling polymer & preservative Allow to stand overnight Product

ENVISAGED OUTCOME OF THE STUDY The outcome of the project would be a comparatively cost effective formulation for treatment of wound healing that will be based on newer nanotechnology. The product will demonstrate adequate stability & safety. After successful safety & stability test and DCGI approval, this project will go to Phase-2 for clinical trail study.

List or marketed product Name of Product Label drug content Manufacturer Price & quantity Silverex Ionic 0.2% Silver nitrate Ranbaxy Rs. 47 for 10g BURNHEAL oint:  Silver sulphadiazine 1 % w/w, chlorhexidine 0.6 % w/w.  Cipla 15g per 20g HYDROHEAL-AM topical gel:  Propylene glycol 4.96 % w/w, carbomer 0.76 % w/w, silver colloid 32 ppm, triethanolamine 0.32 % w/w. Dr. Reddy’s Rs. 69.5 for 15g SILVINDON cream 1% w/w silver sulfadiazine Zydus (Indon) Rs. 11.53 for 20g ALOEDERM-B cream: Aloe vera juice 30 % w/w, vitamin E acetate 0.5 % w/w, allantoin 0.5 % w/w, sodium pyrrolidone carboxylic acid 1 % w/w, silver sulfadiazine 1 % w/w, chlorhexidine gluconate 1 % w/w Fem Care Rs. 33 for 15g

RATIONALE S.No. Limitation of Marketed products Advantage of Proposed Product 1 Silver sulphadiazine costs Rs. 13756 per 25 g http://www.sigmaaldrich.com/catalog/product/aldrich/481181?lang=en&region=IN Silver Nitrate costs Rs. 4143 per 25 g http://www.sigmaaldrich.com/catalog/search?interface=All&term=silver+nitrate&N=0&mode=match%20partialmax&focus=product&lang=en&region=IN 2 Formulation containing silver nitrate in ionic form cause skin staining Silver nanoparticle based product does not cause skin staining 3 Uses Silver sulphadiazine in 1%w/w or Silver nitrate 0.2% Uses 10-3 M Silver nitrate which is 0.016987% w/w

INFORMATION REGARDING IPR Background IP details: Complete Patent Filled IP owned by: Chandra, A., et al. c/o Amity University, Noida Licensing details, if any: Nil

FUTURE PLANS The success of the clinical trial would lead to the scale up, process validation, large scale manufacture and finally commercialization and marketing of the product. This activity would be taken up in the next phase.

Thank You